IMBdx
KOE: 461030.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Tae-You Kim
- Employees
- 58
- Headquarters
- Seoul, South Korea
- IPO year
- 2024
- Market cap
- ₩92.8B
- Website
- http://www.imbdx.com
Loading 461030…
Loading profile data…Frequently asked questions about 461030
What does IMBdx (461030.KQ) do?
IMBdx, Inc. engages in the development of liquid biopsy tests for cancer diagnosis. It focuses on the following business areas: diagnosis and treatment of advanced cancer, early detection of recurrence after surgery, and early cancer diagnosis. Its products include AlphaLiquid, CancerDetect, and CancerFind. The company was founded by Tae-Yu Kim,...
Where does 461030.KQ trade?
IMBdx (461030.KQ) trades on the KOSDAQ.
What sector is 461030.KQ in?
IMBdx (461030.KQ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of IMBdx?
Tae-You Kim is the chief executive officer of IMBdx (461030.KQ).
Where is IMBdx headquartered?
IMBdx is headquartered in South Korea.
Does 461030.KQ pay a dividend?
IMBdx (461030.KQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 461030.KQ go public?
IMBdx (461030.KQ) completed its initial public offering in 2024.